European Long-acting Antipsychotics in Schizophrenia Trial
What is the study about?
EULAST is a large international trial comparing Paliperidone and Aripiprazole; two licensed and commonly prescribed antipsychotic medications. We will be investigating treatment efficacy, compliance rates and any potential side-effects, in both oral and depot administration.
Who can take part?
- Be 18 years or older
- Have a diagnosis of schizophrenia or other psychosis
- The first psychotic episode occurred at least one year and no more than 7 years ago.
Individuals will be unable to take part if they:
- Have been treated with one of the medications included in this study and either did not tolerate the medication or the medication did not have an effect on schizophrenia symptoms
- Are currently treated with clozapine
- Are a forensic patient
What is involved?
Participants are randomised to one of four different treatment groups:
- Oral Paliperidone
- Oral Aripiprazole
- Depot Paliperidone
- Depot Aripiprazole.
Participants in this study will receive this treatment for a period of 18 months. Participants are asked to visit the research clinic monthly for physical monitoring and mental health assessments.
How do I get involved?
If you are interested in taking part or would like some more information please contact Jessica True, Clinical Research Coordinator on 019327 222 47 or firstname.lastname@example.org . Alternatively you can contact the Principle Investigator Dr Nilforooshan.